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Trends box  
 
In T1D, β cells are highly sensitive to selective damage and recruit immune 
cells by chemokine production. These immune cells directly damage β cells 
as well as induce enzymes and cytokines that cause free radical and 
cytokine-induced apoptosis.  
 
Damaged islets express innate immune receptors, engagement of which may 
amplify  cell destruction, contributing to their own destruction. Interestingly, 
damaged and functional islets co-exist. Immune regulatory cells and 
regulatory mechanisms induced by islet cells counterbalance inflammation.  
Communication between immune cells and resident islet β cells during 
inflammation is dependent on the pancreatic microenvironment.  
 
Therapeutically targeting the direct and indirect mediators of islet β cell 
damage to prevent further destruction, combined with boosting islet  cell 
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Abstract 11 
The autoimmune destruction of the pancreatic islet β-cells is due to a targeted 12 
lymphocyte attack. Different T-cellular subsets communicate with each other 13 
and with the insulin-producing β-cells in this process, with evidence not only 14 
of damage to the tissue cells but also lymphocyte regulation. Here we explore 15 
the various components of the immune response as well as the cellular inter-16 
actions that are involved in causing or reducing immune damage to the β-17 
cells. We consider these in the light of the possibility that understanding may 18 
help to identify therapeutic targets to reduce the damage and destruction 19 
leading to type 1 diabetes.  20 
3 
Type 1 diabetes and Islet Inflammation 21 
Type 1 diabetes (T1D) is an organ-specific autoimmune disease that results in 22 
a loss of insulin-producing β-cells (see glossary) in the pancreatic islets of 23 
Langerhans, leading to an inability to maintain glucose regulation (1). Insulin 24 
administration is essential in patients with type 1 diabetes. However, maintain-25 
ing optimal blood glucose is difficult, and many patients present with compli-26 
cations including blindness, kidney failure and vascular complications (1). Alt-27 
hough T1D is T-cell-mediated, other immune cells are crucial for this multi-28 
functional process with a dynamic progression of inflammation. Antigen pre-29 
senting cells (APCs) are critical for antigen presentation of peptides to T-30 
cells (both CD4 and CD8 T-cells), resulting in immunological and molecular 31 
events leading to apoptosis of β-cells (2). Understanding these cellular inter-32 
actions and subsequent events will provide important information to enable us 33 
to identify new targets and deliver potential therapies.   34 
 35 
The autoimmune response in human T1D progresses slowly, and intact islets 36 
can coexist with islets undergoing immune infiltration and β-cell destruction. 37 
Historically, it was thought only when 70-90% of β-cells are destroyed that 38 
clinical symptoms in patients appear, although recent reports suggest this is 39 
overestimated (3, 4). Furthermore, experimental mouse models have demon-40 
strated that leukocyte infiltration into islets does not always lead to disease 41 
(5). We suggest that different islets, within the same tissue, may have a dif-42 
ferent cellular profile with heterogeneous cell types, which may evolve de-43 
pending on the microenvironment they encounter. It is essential to understand 44 
why some insulin-producing -cells are destroyed and some escape destruc-45 
tion. Emerging literature on the dynamics of the pancreatic infiltrate in the 46 
non-obese diabetic (NOD) mouse (Box 1) during the course of diabetes has 47 
shown how diverse and constant cellular flux can be, although not an ‘open 48 
house’ to all cell types (6). Furthermore, work on the antigen-specific T-49 
cell:APC interactions in the islets throughout disease progression has demon-50 
strated that the tissue microenvironment can control T-cell functions and mo-51 
tility (7, 8). During the early stages of inflammation in the NOD mouse, devel-52 
opment of T1D is dependent on crosstalk in the pancreas between islet β-53 
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cells and B-1a cells, neutrophils and interferon alpha (IFNα) secreting 54 
plasmacytoid dendritic cells (pDCs) (9). With these studies in mind, we aim 55 
to discuss cellular interactions in the islets, focusing on islet-resident cells and 56 
the interplay with infiltrating immune cells (Figure 1, Key Figure). This will take 57 
into account different heterogeneous populations and what will be required to 58 
improve our understanding of these complex interactions. We will discuss the 59 
autoimmune processes in the pancreas of mice developing insulitis, but 60 
cross-reference to human pancreas, fully acknowledging that processes may 61 
not be identical. 62 
 63 
Islet Organization and Immune Control 64 
The pancreas consists of exocrine and endocrine tissues that are functionally 65 
distinct. The exocrine cells produce digestive enzymes and will not be dis-66 
cussed here. The endocrine cells maintain glucose homeostasis. Pancreatic 67 
islets comprise multiple hormone-secreting cells that are highly organized; in 68 
rodents, insulin-producing β-cells are at the core of the islet. Other endocrine 69 
cells include the glucagon-secreting  somatostatin-secreting į cells, 70 
pancreatic polypeptide (PP)-secreting cells, and ghrelin-producing İ cells, and 71 
reside in the islet periphery. In human islets, the organization of these endo-72 
crine cells is more intertwined and compact (10). They are highly vascularized 73 
to enable the efficient secretion of insulin into the bloodstream. For a full re-74 
view on in-depth control of insulin release, see (11). 75 
 76 
Immunofluorescence studies demonstrate that pancreatic islets are surround-77 
ed by a peri-islet basement membrane (BM) and an interstitial matrix, that to-78 
gether create a capsule. The BM acts as a barrier for the insulin-secreting β-79 
cells, and leukocytes must pass through this membrane during islet infiltration. 80 
A loss of this capsule, during the progression of diabetes in the NOD mouse 81 
model and human T1D, specifically correlates with leukocyte infiltration (12). 82 
This suggests that the peri-islet BM is a key regulator of islet infiltration and 83 
progression of T1D. Here, it should be noted that mouse and human BM dif-84 
fers in organization, with the human BM having a second BM layer (13). 85 
 86 
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The islets of the pancreas are highly vascularized, and communication be-87 
tween -cells and surrounding cell types is particularly important. -cells are in 88 
close contact and communicate with intra-islet endothelial cells, and normally 89 
this communication maintains homeostasis (14, 15); however this is also im-90 
portant in the context of autoimmune disease (Figure 1A). It is well document-91 
ed, in mice and humans, that cell adhesion molecules on the endothelium in 92 
the pancreas can enable T-cell binding and interactions (16) resulting in T-cell 93 
activation and movement into the islets (17). Additionally, patients with T1D 94 
have increased expression of Major Histocompatibility Complex (MHC) I and 95 
induced expression of MHC II on islet endothelial cells (18, 19), allowing en-96 
dothelial cells to present autoantigens to T-cells (18). This is a potential 97 
mechanism in humans and mice by which T-cells may enter the islets. Finally, 98 
isolated human endothelial cells can express the co-stimulatory molecule 99 
CD86 that is involved in CD4 T-cell adhesion through interaction with cytotox-100 
ic T lymphocyte associated protein 4 (CTLA4), a key negative regulator on T-101 
cells (20). Thus, the highly specialized islet structure and microvascular cells 102 
of the pancreas can facilitate T-cell infiltration and contribute to the progres-103 
sion of disease.  104 
 105 
Influence of β-cells in the islet microenvironment 106 
The β-cell is highly specialized for insulin release but also intra-islet commu-107 
nication and immune regulation of the islet (Figure 1). β-cells are targeted by 108 
diabetogenic T-cells, and upon lysis, β-cells release islet-specific antigens 109 
that trigger or perpetuate inflammation. MHC I expression is upregulated on 110 
both mouse and human β-cells during inflammation (19, 21). Furthermore, 111 
this MHC I expression can influence β-cell destruction by CD8 cytotoxic T 112 
lymphocytes (CTL); mice lacking MHC I expression on β-cells have reduced 113 
diabetes incidence (17, 22). Historically, presentation of murine islet-specific 114 
antigens to CD4 T-cells by -cells requires APC help (23, 24). However, more 115 
recent evidence suggests that murine islet -cells can upregulate MHC II dur-116 
ing inflammation and present antigen to diabetogenic CD4 T-cells in vitro (25). 117 
Interestingly, co-stimulatory molecule expression has not been found on β-118 
cells (25), and therefore it is possible that β-cells present antigen in vivo to 119 
6 
induce anergic CD4 T-cells to control inflammation. However, the function of 120 
CD4 T-cells stimulated by β-cells has yet to be established. MHC II expres-121 
sion (HLA) can be found on human -cells in insulin-containing islets, but ap-122 
pears to be limited to a small number of cells (26, 27). This expression is ob-123 
served without insulitis present, suggesting upregulation just prior to infiltration 124 
(27).  125 
 126 -cells are also a source of chemokine production, which may have inflamma-127 
tory or protective roles in both the NOD mouse and human islets (28, 29). 128 
Multiple chemokines including C-X-C motif chemokine 10 (CXCL10) are up-129 
regulated on -cells in islets undergoing infiltration (28, 29), which drives im-130 
mune cell recruitment to the pancreas via the chemokine receptor CXCR3 131 
(28). Human islet -cells express the Interleukin-22 receptor (IL-22R) (30), 132 
which can be engaged by IL-22 produced from T-cells, in patients with T1D 133 
(31). IL-22 up-regulates genes that protect -cells from apoptosis and can en-134 
hance -cell regeneration (32). During inflammation, cytokines such as IFN, 135 
in the presence of IL-22, can induce nitric oxide synthase (iNOS) and resulting 136 
oxygen free radicals contribute to tissue destruction (33). This is pertinent in 137 
T1D, as IFN production in the pancreatic islets is essential for disease initia-138 
tion (9). Conversely, however, in NOD mice deficient in IFNα receptor 1 (IF-139 
NAR1) diabetes is not delayed or prevented (34). Synergistic islet interac-140 
tions, under pro-inflammatory conditions, have also been demonstrated in 141 
both rat and human islets (35, 36). In the presence of interleukin 1 (IL-1) - 142 
cells undergo destruction in an iNOS dependent manner (36). Production of 143 
IL-1 can be induced in islet macrophages by tumor necrosis factor alpha 144 
(TNF) and lipopolysaccharide (LPS) stimulation, and depletion of islet mac-145 
rophages inhibits expression of IL-1 (36). 146 
 147 
In common with other tissue cells, both endocrine as well as infiltrating im-148 
mune cells may express innate immune receptors (reviewed in (37)). Whilst 149 
these receptors are normally involved with the detection of pathogen-induced 150 
molecular patterns (PAMPs), they may also sense damage-induced molecular 
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patterns (DAMPs) (37). Thus, inflammation within islets may be amplified by 152 
recognition of molecules released by islet damage (37). 153 
 154 
Regulatory costimulatory molecules may also be important. -cells express 155 
programmed death-ligand 1 (PD-L1) during insulitis and may play a key role 156 
in regulating inflammation, demonstrated by the NOD-Pdcd1-/- mice that have 157 
PD-L1 deficiency and develop accelerated diabetes (38, 39). Patients receiv-158 
ing anti-programmed death 1 (PD-1) treatment for cancer can present with 159 
autoimmune T1D (40). It is clear that although -cells are key in tissue regula-160 
tion and homeostasis, they can self-destruct when exposed to certain envi-161 
ronmental cues. However, we have yet to gain full understanding of -cell 162 
communication with immune cells through this pathway, during different stag-163 
es of inflammation. Critical interactions in the evolving microenvironment, in-164 
volving both soluble factors as well as cell-to-cell contact need to be uncov-165 
ered. It is also interesting to speculate that E-cadherin, a key protein involved 166 
in adhesion on epithelial tissues, in the pancreatic islets may interact with its 167 
ligand CD103, expressed on effector memory CD8 T-cells, which can reside 168 
in non lymphoid tissues (41). In a model of pancreatic islet transplant rejec-169 
tion, CD8+CD103+ T-cells are found at the graft site and are essential during 170 
the immune response (42). Together, islet -cells are integral in regulating the 171 
local environment, but during inflammation, multiple mechanisms can contrib-172 
ute to their own cell death. 173 
 174 
Islet Antigen Presenting Cells (APCs) 175 
Myeloid tissue resident cells in the pancreas play a key role in tissue homeo-176 
stasis as well as in inflammatory conditions. Islet APCs are needed for normal 177 
islet function (43). In the murine islet, two main APC subtypes have been 178 
identified. The islet mostly contains APCs that are CD11c+CD11b+ F4/80+ 179 
CD80+ and express MHC II (44), consistent with a macrophage phenotype 180 
(45). A smaller population lacking CD11b but expressing CD103 (CD11c+ 181 
MHC II+) (46), consistent with a dendritic cell (DC) population has been identi-182 
fied (45, 47). These APC subsets are in close contact with islet blood vessels, 183 
as shown by two-photon microscopy (46, 48), suggesting these APCs are in-184 
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volved in surveillance of surrounding areas. Further to this role, islet APCs are 185 
essential for islet antigen presentation, and express MHC-peptide complexes 186 
derived from β-cell proteins (44). They are efficient at presenting these pep-187 
tide complexes to CD4 T-cells. -cells transfer secretory granules to resident 188 
islet APCs and it is this interaction that allows the recognition of -cell anti-189 
gens by CD4 autoreactive T-cells (49). 190 
 191 
Tissue resident CD103+ DCs, which are of the same lineage as CD8α DCs 192 
found in lymphoid tissues (50), are under the control of the Batf3 transcription 193 
factor (51) and are a key DC subset presenting MHC I-bound peptides to CD8 194 
T-cells. Interestingly, this DC population was increased in the islets of pre-195 
diabetic NOD mice (12 weeks of age), which synchronized with CD4 T-cell 196 
infiltration (47). Furthermore, Batf3-/- mice do not develop spontaneous diabe-197 
tes as a result of lack of antigen presentation to antigen-specific CD4 T-cells 198 
in the islet and diminished CD8 T-cell priming in the pancreatic lymph node 199 
(47). This suggests that CD103+ DCs are essential for autoimmune diabetes. 200 
More recently, the importance of the pancreatic milieu on macrophage pheno-201 
type has been shown in the C57BL/6 mouse model (52) but is yet to be tested 202 
in NOD mice. Furthermore, the islet microenvironment influences macrophag-203 
es, demonstrated in mice lacking NADPH oxidase (NOX)-derived superoxide 204 
(an enzyme complex involved in free radical production), which display an al-205 
ternatively activated M2 macrophage phenotype and have delayed onset di-206 
abetes (53) (reviewed in (54)).    207 
 208 
Heterogeneous populations of myeloid cells are present in the murine islet 209 
during inflammation, including recruited populations of macrophages and DCs 210 
(6, 7). pDCs producing IFN, essential for disease initiation, are present in the 211 
islets during early stages of insulitis (9). In line with this, pDCs are increased 212 
in peripheral blood of newly-diagnosed, but not long-standing patients (55). In 213 
contrast, in the NOD mouse model, pDCs can negatively regulate diabetes as 214 
their loss leads to accelerated insulitis (56). This disparity suggests that pDCs 215 
may have dual roles in T1D, dependent on the environment and cell milieu 216 
present in the islet. APC populations alter with the severity of islet inflamma-217 
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tion and mediate T-cell:APC interactions, and in turn change T-cell effector 218 
function (7). This further demonstrates the importance of the evolving micro-219 
environment in the pancreas. Importantly, new imaging techniques will enable 220 
the visualization of multiple islets, allowing further understanding of the vary-221 
ing infiltration in each islet (7, 8). 222 
 223 
Islet infiltrating T-cells 224 
T-cells are essential in the development of diabetes, although other popula-225 
tions are required for full clinical manifestation. Evidence accumulated over 226 
many years has shown that CD4 and CD8 T-cells are directly involved in the 227 
destruction of -cells, particularly in mouse models (57). In recent years, the 228 
topic of antigen specificity has been widely discussed, with conflicting hypoth-229 
eses. Whether islet entry is dependent on antigen specificity, or whether T-cell 230 
infiltration is controlled by chemokine and cytokine cues, is a much-231 
researched question. Additionally, whether islet infiltration is largely autoreac-232 
tive, or whether bystander T-cells are present during this inflammation, has 233 
also been an important focus and conclusions have differed, dependent on 234 
the methodology used. Sophisticated retrogenic mouse models, whereby 235 
hematopoietic stem cells are transduced with a retroviral construct containing 236 
the TCR α and β chains encoding T-cell receptors from diabetogenic T-cell 237 
clones and then infused into recipient mice, have demonstrated that bystand-238 
er T-cells do not infiltrate pancreatic islets (58). Furthermore, work on the initi-239 
ation of events revealed that antigen-specific CD4 T-cells are the first T-cells 240 
to infiltrate the pancreas and interact with local intra- islet APCs (48). This first 241 
interaction induces changes in the local microenvironment, including vascular 242 
cell adhesion molecule 1 (VCAM-1) upregulation on the endothelium of islet 243 
blood vessels and intercellular adhesion molecule 1 (ICAM-1) upregulation on 244 
islet -cells. These events allow subsequent infiltration of non-antigen-specific 245 
CD4 T-cells (59). The initial entry of CD4 T-cells is supported by further stud-246 
ies in the NOD model demonstrating that only CD4 T-cells were detected in 4 247 
week-old mice; CD8 T-cells and B-cells are found at 6 weeks old within the 248 
islet; by 8 weeks all major leukocyte subsets have infiltrated (60). However, 249 
antigen specificity was not probed in this study. A new investigation using the 250 
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Kaede/NOD mouse model, which allows non-invasive labeling and tracking of 251 
cells, reported that not all CD4 T-cells that infiltrate the islets are antigen spe-252 
cific; in fact activated effector memory CD4 T-cells were a minority of the pop-253 
ulation found in the islets (6). Detection of antigen specific CD4 T-cells in hu-254 
mans with T1D is challenging given the low frequency of antigen specific T-255 
cells. Recently, however, recently islets isolated from a patient with T1D re-256 
vealed CD4 T-cells responsive to proinsulin peptides (61). The degree of het-257 
erogeneity of CD4 T-cells that recognize β-cell epitopes within individuals with 258 
T1D remains unknown.     259 
 260 
In respect of CD8 T-cell antigen specificity, studies in mice show MHC class I 261 
expression and local antigen recognition is required for the homing of CD8 T-262 
cells to the pancreas (17, 62). However, this does not exclude the possibility 263 
that chemokine and cytokine cues are also important (17, 63). Earlier murine 264 
studies of antigen-specific CD8 T-cells indicated that whilst less numerous 265 
than CD4 T-cells, CD8 T-cells can be found within the islet in the early infil-266 
trate (64, 65). Recently, CD8 T-cells specific for islet autoantigens have been 267 
found in human islet tissue from both newly diagnosed and long standing pa-268 
tients (66). Of note, CD8 T-cells were found to recognize multiple islet autoan-269 
tigens only in long standing patients, building a case for persistent antigen re-270 
lease (66). In mice, CD8 T-cells acquire an effector memory phenotype in the 271 
islets that have increased expression of IFNȖ and granzyme B, indicating en-272 
counters with cognate antigen (67, 68). Further to this, tetramer-stained anti-273 
gen-specific CD8 T-cells upregulate KLRG1 and CD127, markers associated 274 
with antigen exposure (69). Another marker associated with chronic antigen 275 
stimulation is PD-1, a key negative regulator and expressed on exhausted 276 
CD8 T-cells, particularly in viral infections. An exciting study recently revealed 277 
that exhausted CD8 T-cell transcriptional profiling could predict the prognosis 278 
of autoimmune disease, including T1D (70). However, whether CD8 T-cell ex-279 
haustion occurs in the pancreatic islets during inflammation has yet to be de-280 
termined (outstanding questions), but it is an interesting possibility, as de-281 
struction of β-cells releases further antigen, perpetuating chronic exposure. 282 
Additionally, IL-7 receptor blockade in the NOD mouse model can prevent and 283 
reverse diabetes by the induction of PD-1 upregulation and reduced IFNȖ 284 
11 
production in CD4 T-cells (71). PD-1 expression on both CD8 and CD4 T-cells 285 
may provide a regulatory mechanism by interaction with its ligand on β-cells in 286 
the islets during autoimmune diabetes (See Figure 1).  287 
 288 
Regulatory T-cells (Tregs) are a well-studied population in T1D, as dysregu-289 
lation leads to spontaneous autoimmunity in humans. There is also evidence 290 
that Treg function is impaired in human T1D (72). In mouse models, Treg 291 
adoptive transfers can protect mice from T1D and manipulation of Treg 292 
mechanisms can accelerate disease progression (73). The transcription factor 293 
required for Treg function, forkhead box P3 (FoxP3), is a hallmark of natural 294 
Treg cells. Ablation of FoxP3 T-cells in a CD4 double transgenic model using 295 
an inducible system demonstrated accelerated immune attack on islets, char-296 
acterized by increased effector T-cells and activated natural killer cells (NK 297 
cells) (74). This has led to therapeutics aiming to increase Tregs, such as IL-2 298 
injections, which increases Tregs in the pancreatic islets, resulting in reversal 299 
of established disease (75). Recently, the full extent of Treg interaction with 300 
other cells in the pancreatic islets has been more thoroughly investigated. 301 
Treg treatment in a mouse model of accelerated diabetes revealed that Tregs 302 
not only inhibit CD4 T-cell effector function in the islets, but also have a pro-303 
found effect on CD8 T-cells (76). Here, CD8 T-cells were fewer in Treg-304 
treated mice, though this was not a result of apoptosis or inhibition of prolif-305 
eration but reduced chemokine recruitment. Furthermore, Tregs had the abil-306 
ity to inhibit IFNȖ production from CD8 T-cells through mTOR signaling direct-307 
ly in the target tissue.  308 
 309 
Islet Infiltrating B-cells 310 
B-cells play an important role in the pathogenesis of T1D, including insulin-311 
specific antigen presentation to CD4 T-cells, and the production of pro-312 
inflammatory cytokines, both contributing to the destruction of islet β-cells. B-313 
cell depletion therapy using an anti-human CD20 (hCD20) monoclonal anti-314 
body can reverse diabetes in the hCD20 transgenic NOD mouse model (77), 315 
as could targeting CD22 (78). For a full review of B-cell depletion therapy in 316 
type 1 diabetes in both humans and mice see (79). During inflammation, infil-317 
trating B-cells can be organized into tertiary lymphoid structures (TLS) (80), 318 
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including germinal centers. Molecular analysis of the B-cell receptors (BCR) in 319 
TLS shows a different light chain usage, compared to the pancreatic lymph 320 
node (80). This suggests that islet-infiltrating B-cells are specific to the pan-321 
creas and do not reflect the repertoire of B-cells found in the secondary lym-322 
phoid organs. Supporting this, B1a-like B-cells (found mostly in the peritone-323 
um), that are CD5+ B220low, infiltrate islets in NOD mice (81). Furthermore, B-324 
cells in the pancreatic islets are mostly antigen-specific and show markers of 325 
antigen experience (80, 82, 83). Taken together, the evidence suggests that 326 
there is specific cross-talk between B-cells and T-cells in the islets during in-327 
flammation. This interplay between B- and T-cells has been dissected by the 328 
use of B-cell depletion therapy. B-cell depletion can improve the outcome of 329 
diabetes in part by the induction of Treg subsets (77, 78), although this occurs 330 
only during the reconstitution of B-cells. In fact, before B-cell reconstitution, 331 
antigen-specific CD4 T-cells respond more robustly to antigen in vitro, and a 332 
reduction of CD4 Tregs was observed in the islets, compared to non-depleted 333 
control mice (84). However, once B-cell populations are restored, they acquire 334 
enhanced regulatory function that depends on cell-to-cell contact rather than 335 
IL-10 (84). It is important to note that B-cells infiltrating islets can become 336 
plasma cells and lack CD20 expression (85). In humans, CD20lo and CD20high 337 
B-cells are found in the islets of patients, which represent different profiles of 338 
insulitis correlating with diagnosis (4). Together this may impact on the effica-339 
cy of anti-CD20 B-cell therapy. 340 
 341 
Other studies using B-cell depletion show an impact on other cell subsets. B-342 
cell absence during TNFα-mediated inflammation impacts CD8 T-cell accu-343 
mulation in the islet, with increased apoptosis, resulting in fewer intra-islet 344 
CD8 T-cells (86). B-cell depletion also expands CD11b+Gr1+ myeloid popula-345 
tion that can suppress T-cell function through IL-10, NO and cell contact (87). 346 
It is clear that B-cells significantly alter the progress of inflammation, and in 347 
their absence, key interactions in the islet can be altered to favor tissue regu-348 
lation (See Figure 2).  349 
 350 
Conversely, B-cells have also been reported to regulate autoimmunity, includ-351 
ing T1D. Different regulatory B-cell (Bregs) populations have been de-352 
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scribed that regulate through anti-inflammatory cytokines such as IL-10, TGF 353 
and IL-35. The participation of Bregs in the islets during insulitis is relatively 354 
undefined; possible interactions are shown in Figure 3 for the NOD mouse 355 
and we speculate that this is also possible in humans. B-cells activated with 356 
LPS can produce TGFβ and express Fas ligand and leads to the apoptosis of 357 
diabetogenic T-cells (88). In addition, Bregs can induce Tregs, possibly 358 
through a TGFβ mechanism and promote graft survival (89). Interestingly, in-359 
creased IL-10 levels from B-cells in the islets of long-term normoglycemic 360 
mice have been reported (90). Moreover, increased populations of CD40+ and 361 
anergic B-cells are also found in islets of mice that are ‘protected’ from diabe-362 
tes (90). Whether this altered B-cell repertoire is functionally impaired or 363 
negatively regulating the microenvironment is yet to be determined. Of note is 364 
that IL-35 can induce IL-10 producing B-cells (91) and ectopic expression of 365 
IL-35 on -cells can protect from diabetes and -cell destruction (92). Alt-366 
hough this IL-35 ectopic expression resulted in decreased CD8 and CD4 T-367 
cells, the effect on B-cells was not addressed in the study. Emerging literature 368 
also reveals new populations of Breg cells, including Tim-1-expressing Bregs 369 
that are able to alter T-cell responses and reduce the severity of EAE (exper-370 
imental autoimmune encephalomyelitis) through an IL-10-dependent mecha-371 
nism (93). Recent evidence describes pDC production of IFN, along with 372 
CD40 stimulation, induces IL-10-producing immature Bregs, and this pathway 373 
is altered in patients with systemic lupus erythematosus (SLE) (94). It is inter-374 
esting to speculate whether the conflicting roles of IFN and pDCs seen in 375 
T1D contrasting with this recent data in SLE may be an unexplored mecha-376 
nism providing insight into new regulatory pathways. Whether these popula-377 
tions of Bregs are present in the pancreatic infiltrate or important in T1D is a 378 
question that is yet to be answered. 379 
 380 
Other regulatory cell populations include invariant NK T-cells that may interact 381 
with potential Breg populations may also be present in ‘protected’ NOD mice 382 
(See Figure 3). 383 
 384 
Concluding remarks and future perspectives 385 
14 
T1D is a multifactorial autoimmune disorder that leads to β-cell destruction. It 386 
is clear that more than one immune cell population governs local inflamma-387 
tion. Resident islet cells play a role in tissue regulation but also contribute to 388 
tissue destruction. The protection of  cells within the islet requires a dynamic 389 
balance of a heterogeneous population of cells, all of which provide specific 390 
signals. It would be useful to understand the factors that upset this balance 391 
(outstanding questions).   392 
More examination is required into the heterogeneity of islets within the pan-393 
creas with regards to their immune infiltrate and the status of islet resident 394 
cells. Understanding the contribution of these resident cells may allow differ-395 
entiation between pathogenic and potentially protective mechanisms (out-396 
standing questions).  The triggers of -cell destruction are important, but we 397 
should be particularly interested in the immune phenotype of islets that have 398 
immune cell infiltrates but do not undergo -cell destruction (see outstanding 399 
questions). This would allow consideration of how best to target the multiple 400 
cell types that contribute to -cell destruction and their interaction with the -401 
cells (Text box 2). 402 
 403 
Understanding both the pathogenic pathways as well as the regulatory com-404 
ponents that reduce islet -cell damage is important, as we seek to develop 405 
immunotherapy to reduce loss of insulin production in diabetes. Ultimately, 406 
boosting natural regulation or protective pathways may be equally important in 407 
protection of -cell regeneration or replacement in immunotherapy and pre-408 
vention of type 1 diabetes.  409 
 410 
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Glossary  419 
Antigen Presenting Cell (APC): A cell that can present antigens via either 420 
MHC I or MHC II. 421 
B1-a cells: A subset of B lymphocytes mainly localized in the peritoneal cavi-422 
ty that are involved in humoral immunity. 423 
Basic leucine zipper transcriptional factor ATF-like 3 (Batf3): A transcrip-424 
tion factor that controls the maturation of CD8 classical dendritic cells. 425 
Beta-(β) cells: Resident islet -cells responsible for secreting insulin into the 426 
bloodstream. These cells are the primary target during autoimmune type 1 di-427 
abetes.  428 
CD4 T-cell: A T lymphocyte, which is part of the adaptive immune system, 429 
that expresses a CD4 molecule (part of the T-cell receptor) on the surface that 430 
upon recognition of antigen presented by MHC II produces cytokines. 431 
CD8 T-cell: A T lymphocyte, which is part of the adaptive immune system, 432 
that expresses a CD8 molecule (part of the T-cell receptor) on the surface that 433 
is involved in targeted killing upon recognition of antigen presented by MHC I.   434 
Insulitis: Infiltration of immune cells into the Islets of Langerhans. 435 
Islets of Langerhans: Islands of endocrine tissue within the large body of 436 
pancreatic acinar tissue making up 1-2% of the total cell mass. 437 
M2 macrophage: A group of heterogenous macrophages that can be alterna-438 
tively activated by cytokines such as IL-4 and IL-13. These cells are involved 439 
in tissue repair and wound healing.   440 
Plasmacytoid DCs (pDCs): A unique subset of dendritic cells which play a 441 
role in antiviral immune responses and specializes in the production of inter-442 
ferons, and importantly interferon alpha (IFN) in the context of T1D.  443 
Programmed death-ligand 1 (PD-L1): A ligand for PD-1 which is expressed 444 
on multiple cell types including lymphocytes and myeloid cells. 445 
Programmed death-receptor (PD-1): A cell surface receptor expressed on 446 
lymphocytes that can deliver essential negative signals to T and B cells upon 447 
ligation with its ligands 448 
Regulatory B-cells (Breg): A heterogeneous group of B lymphocytes defined 449 
by immunoregulatory function. 450 
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Regulatory T-cells (Treg): A specific population of T lymphocytes that have 451 
the ability to suppress effector T-cell responses. 452 
Retrogenic mouse: A mouse developed using retrovirus technology which 453 
allows the study of multiple T-cell receptors simultaneously.  454 
 455 
Box 1. Islet inflammation and kinetics of the NOD mouse 456 
The use of the NOD mouse model has provided many advances and insights 457 
into human T1D, because it has allowed study of the kinetics and initiation of 458 
diabetes. The importance of the NOD mouse model has been extensively dis-459 
cussed in reviews (57, 95). This animal model develops diabetes spontane-460 
ously with genetics and pathological outcomes that parallel those of human 461 
T1D (95). Genetically, the NOD mouse expresses MHC II molecules I-Ag7, 462 
which is the primary contributor to disease susceptibility (95). Corresponding-463 
ly, the genetic region strongly associated with T1D in humans is the HLA lo-464 
cus; however, in both mice and humans, environmental factors are also a 465 
contributing factor (1). Disease incidence in NOD mice is higher in females 466 
than in males at about 70-80% compared to 20-30%, respectively, and varies 467 
between different laboratory colonies (2). Inflammatory cells can be observed 468 
in the islets as early as 2-4 weeks of age in the NOD mouse. Infiltration of the 469 
islets continues to amplify, inducing -cell death, causing the full clinical mani-470 
festations of diabetes (2). In comparison, human T1D is very slow and insulitis 471 
seems to be less extensive with regards to the amount of cellular infiltrate and 472 
proportion of islets compromised (4). In both human and mouse, this infiltra-473 
tion comprises a variety of leukocytes, including lymphocyte populations such 474 
as CD4 and CD8 T-cells, B-cells, in addition to myeloid populations and NK 475 
cells (96). In the NOD mouse, innate immune cells can be detected in the 476 
pancreas, including neutrophils, plasmacytoid DCs and B-cells, as early as 2 477 
weeks of age (9). Myeloid cell populations comprise the majority of the im-478 
mune cells during early stage insulitis, then lymphocyte populations become 479 
more prominent as disease is established (6). In mice, CD4 T-cells are more 480 
numerous in the islet lymphocyte population, although in humans CD8 T-cells 481 
are more prominent (6, 96, 97). It is important to note that some NOD mice 482 
are ‘protected’ from diabetes (aged 30 weeks onwards), as the incidence is 483 
17 
rarely 100%, and even more noteworthy is that these mice still have islet infil-484 
tration although do not succumb to full clinical disease (90). Moreover, there 485 
are well known transgenic mouse models that develop pancreatic infiltrate yet 486 
do not present with spontaneous disease (5, 98). This interesting observation, 487 
along with the parallel existence of intact and destroyed islets in the same 488 
pancreas, raise many important questions that need future clarification.  489 
 490 
Box 2. Therapies and therapeutic targets  491 
 492 
There are a number of potential therapeutic targets for T1D. 1) The pathogen-493 
ic T-cells could be directly disabled or destroying indirectly controlled by 494 
boosting regulatory cell activity, reviewed in (99). 2) The APCs that present 495 
antigens to pathogenic T-cells, both in the islet (resident APCs) and in sec-496 
ondary lymphoid organs could be tolerized such that they fail to acti-497 
vate/tolerize T-cells. Tolerizing B-cells as antigen-specific APCs, may be part 498 
of this strategy. 3. The -cells that are the target of the specific damage need 499 
to be protected and allowed to replicate/regenerate (100). Disabling the inter-500 
actions within the islet may be more difficult, but reducing damage by oxygen 501 
free radicals within the islet and boosting -cell repair and regeneration would 502 
be of considerable benefit. Currently there is a gulf between experimental 503 
therapeutic strategies that have been successful in animal models and those 504 
that can be practically targeted in heterogeneous human individuals with T1D. 505 
Many successful strategies have targeted the pre-diabetic period in the NOD 506 
mouse, and if safety and accurate identification of individuals could be made, 507 
then some of the currently successful strategies in mouse models could be 508 
tested in humans. However, once diabetes occurs, relatively few strategies 509 
targeting immune cells have been successful in mice, and this underlines the 510 
difficulty that has also been experienced in immunotherapy in humans. Ideal-511 
ly, therapy would target pathogenic lymphocytes, as well as deal in combina-512 
tion with  cell regeneration (100).  513 
 514 
Figure legends  515 
 516 
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Figure 1. Pancreatic islet cells are involved in immune cell regulation during 517 
inflammation in T1D.  518 
A pancreatic islet (bottom right) is depicted with an immune infiltrate and un-519 
dergoing β-cell destruction. 1. Immune cells entering the pancreas are influ-520 
enced by islet endothelial cells. Endothelial cells enable T-cell adhesion and 521 
binding along with induced expression of MHC I and MHC II allowing antigen 522 
presentation to CD4 and CD8 T-cells. 2. β-cell interactions with islet infiltrate 523 
influence the microenvironment. (A) Antigen presentation by β-cells to CD8 T-524 
cells via MHC Class I can initiate cytotoxic CD8 T-cells to target β-cells, allow-525 
ing antigen release and perpetuation of β-cell apoptosis. β-cell antigens are 526 
processed by DCs and presented via MHC Class II by DCs to CD4 T-cells; 527 
direct presentation through upregulation of MHC Class II may also induce 528 
anergic CD4 T-cells. (B) β-cells express the IL-22 receptor (IL-22R), engaged 529 
by IL-22 produced by CD4 T-cells, allowing protection from apoptosis and en-530 
couraging β-cell regeneration (left). In the presence of IFNα and inflammation, 531 
engagement of IL-22R may lead to tissue destruction (right). 3. β-cells may 532 
modulate the islet environment via PD-L1. PD-L1: PD-1 interaction on CD4 T-533 
cells can lead to a down-regulation of the inflammatory cytokine IFNȖ. Antigen 534 
release from apoptotic β-cells may induce PD-1 up-regulation on CD8 T-cells 535 
upon which engagement with PD-L1 on β-cells and macrophages can, in turn, 536 
down-regulate CD8 T-cell activation. Together these will have an indirect ef-537 
fect on β-cell destruction.  538 
 539 
Figure 2. B cell depletion reveals key immune cell interplay within the pan-540 
creas.  541 
Evidence from B-cell depletion studies suggest that removal of B-cells from 542 
the pancreas can (A) induce a population of IL-10 producing myeloid popula-543 
tion (B) increase apoptosis in intra-islet CD8 T-cells and (C) allow expansion 544 
of CD4 Tregs during B-cell reconstitution which influences antigen presenting 545 
cells (APCs) to down-regulate CD4 and CD8 T-cell activation. This has the 546 
potential to regulate the immune cell environment within the islet in addition to 547 
the systemic effect. 548 
 549 
19 
Figure 3. Proposed interactions between regulatory B-cell populations local 550 
islet inflammatory milieu in the NOD mouse.  551 
Bregs can be induced with a variety of stimuli including CD40 ligation, TLR 552 
ligands and cytokines IL-21, IL-35, IL-1β and IL-6. Plasmacytoid DCs (pDC) 553 
producing IFNα along with CD40 ligation also promote Bregs. Bregs can con-554 
trol inflammation through the production of IL-10, IL-35 and TGFβ and the in-555 
duction of Tregs. IL-10, IL-35 and TGFβ cytokines can all inhibit CD4 T effec-556 
tor cells (Teff), cytotoxic CD8 T-cells and pro-inflammatory cytokines from 557 
dendritic cells (DCs), which in turn down-regulate T-cells. In protected mice, 558 
increased surface expression of CD40 and IL-10 production has been shown 559 
(red boxes) in the pancreatic islets, although we speculate as to the type of 560 
Breg present and how they are induced/maintained. Interactions in the islets 561 
between Bregs and invariant NKT (iNKT) cells may provide further regulation 562 
of diabetogenic T-cells. We also consider that IL-10-expressing Breg can in-563 
fluence macrophage populations that are involved in immunoregulation and 564 
tissue remodeling.    565 
20 
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Outstanding questions box  
 
What are the triggers that lead to immune β cell destruction? Do the islets play an 
active role in this process? Can the process be halted before diabetes manifests? 
 
What is the difference between islets with insulitis but no  cell destruction compared 
to islets undergoing destruction? Are the islet endocrine cells themselves 
contributing to regulation of the infiltrating immune cells or is this protection carried 
out by islet-resident immune cells?  Do protected NOD mice have a different immune 
cell phenotype in the islets compared to NOD mice that develop diabetes? Is this 
protection governed by local Breg interactions? 
 
CD8 T cells are key effectors in  cell destruction. Is there any evidence of CD8 T 
cell exhaustion, indicated by upregulation of PD-1, and could this be a potential 
regulatory mechanism within the target tissue? 
 
Tissue resident CD8 T cells (Trm) have recently been characterized; could Trm cells 
take up residency in islets of the pancreas over time and contribute to the CD8 T cell 
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